Literature analysis of aplasia anemia/pure red cell aplasia induced by pembrolizumab
- VernacularTitle:帕博利珠单抗致再生障碍性贫血/纯红细胞再生障碍性贫血的文献分析
- Author:
Yue LI
1
;
Shichao ZHANG
1
;
Cheng XIE
1
;
Jianguo ZHU
1
;
Yun LI
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215000，China
- Publication Type:Journal Article
- Keywords:
pembrolizumab;
aplastic anemia;
pure red cell aplasia;
literature analysis
- From:
China Pharmacy
2025;36(6):737-741
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the clinical characteristics of aplastic anemia （AA）/pure red cell aplasia （PRCA） induced by pembrolizumab， and provide reference for clinical safe drug use. METHODS Using search terms as “pembrolizumab”， “keytruda”， “anemia” and “aplastic anemia” in both Chinese and English， the literature related to AA/PRCA induced by pembrolizumab were retrieved from PubMed， Embase， CNKI， Wanfang and VIP databases， and then analyzed descriptively and statistically. RESULTS A total of 10 patients were included from 10 literature； among these 10 patients， there were 5 males and 5 females， with 5 patients being aged 65 or above. The primary disease was mainly metastatic melanoma （4 cases）. AA/PRCA occurred 13 d-3 years after the first dose of pembrolizumab. The main clinical manifestations included fatigue， dyspnea， oral/nasal bleeding， diffuse purpura， etc.； 8 cases developed moderate anemia and 2 cases developed severe anemia. After discontinuation and receiving supportive therapy， 5 cases improved， 1 case worsened in anemia， and 4 cases died. CONCLUSIONS When using pembrolizumab in clinical practice， blood routine should be regularly monitored. When AA/PRCA and other related symptoms occur， pembrolizumab should be stopped in time and a therapy regimen should be formulated according to the patient’ condition， to ensure the safety of medication.
